Serum Institute of India Ltd, India's largest vaccine manufacturer, have launched Td-Vac, India's first indigenous tetanus and diphtheria vaccine for combating fatal tetanus and diphtheria (Td) in adolescents and adults.

The Td vaccine is different from the normal DT (dual antigen) vaccine used in children. This new Td vaccine will replace the existing usage of TT (tetanus) vaccine, which is normally given post-injury, states a company release.

According to Dr. Cyrus Poonawalla, chairman, Serum Institute of India Ltd., "Serum Institute has always looked at launching international standard life saving vaccines in the Indian market. Health authorities in the western countries advise the use of Td (tetanus and diphtheria) vaccine instead of the TT (tetanus) vaccine. Now, with the launch of Td-vaccine, India's first indigenous Td vaccine, we are yet again offering the Indian masses the benefit of two vaccines in one, and which is the norm in developed countries."

Td-Vac, priced at Rs. 7.50, provides safety against diphtheria and tetanus (Td), while the tetanus (TT) vaccine is priced at Rs. 6.50.

The incidence of diphtheria has doubled in the last one year and the mortality rate of 20% in India is also very high. Diphtheria is most common in crowded areas with poor sanitation.

The Indian Academy of Paediatrics (IAP) recommends the use of Td vaccine in all individuals over the age of 7 years.

Serum Institute of India is the world's largest DTP (triple) and measles vaccine manufacturer and has been responsible for bringing down the prices of hepatitis-B vaccines in India. The company's products are exported to over 140 countries worldwide.